MiRNA-146a-5p is up-regulated in primary astrocytes treated with FAβ1–42 peptides, and its expression is dependent on the NF-κB pathway. (A) Relative expression of miRNA-146a-5p in primary astrocytes was 0.5, 1, and 2 µM of FAβ1–42 peptides for 3 days in tissue culture. (B) Relative expression of miRNA-146a-5p in primary astrocytes as function of treatment with 2 µM of FAβ1–42 solution in the presence of 5 µM of BMS-345541, IκB kinase pharmacology inhibitor. As positive control, cells were treated with LPS (100 ng/mL). (C) Relative expression of IRAK-1/2 and TRAF-6 in astrocytes treated with 2 µM of FAβ1–42 peptides. Data are represented as the mean ± SEM performed in triplicate. Statistical comparisons between FAβ1–42-treated cells and control, DMSO-treated cells were performed with a Student’s t-test. * p ≤ 0.05, ** p ≤ 0.01.